Reducing the number of variables in these improves the stability of some published estimates
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
So, if thats you, Wegovy isnt the right fit
Sculptra, Radiesse (biostimulatory use), EZgel / PRF
Over the past few years, the conversation around GLP-1 receptor agonists has been dominated by extremes: dramatic weight loss in clinical trials, before-and-after transformations on social media, and a public discourse that has oscillated between miracle and backlash
R.GrossE